uploads///marijuana _

Marijuana-Focused Biotech Companies in Q3: Are They Performing?

Mike Benson - Author

Oct. 5 2018, Published 11:08 a.m. ET

Marijuana-focused biotech companies

Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.

The above chart compares the normalized stock prices for the above-mentioned companies since January.

Article continues below advertisement

GW Pharmaceuticals

GW Pharmaceuticals (GWPH), a biotechnology company, develops and commercializes products based on its cannabinoid product platform. Its stock rose 15.7% in the third quarter. It has increased 24.3% year-to-date to close at $164.07 on October 3.

Cara Therapeutics

Cara Therapeutics (CARA), a clinical stage biotechnology company, develops and commercializes chemical entities based on kappa opioid receptors for the treatment of pruritus and pain management. CARA stock rose ~12.5% in the third quarter and has increased 84.8% year-to-date to close at $22.62 on October 3.


Insys Therapeutics (INSY), a specialty pharmaceutical company, develops and commercializes supportive care products, including Subsys (fentanyl sublingual spray) and cannabinoid products. INSY stock rose ~36.9% in the third quarter and 2.9% year-to-date to close at $9.90 on October 3.

We’ll look at analysts’ estimates, recommendations, valuations, and revenue performances for these companies in this series.

The iShares Nasdaq Biotechnology ETF (IBB) holds 0.5% of its total investments in GW Pharmaceuticals (GWPH), 0.1% in Cara Therapeutics (CARA), 0.1% in Insys Therapeutics (INSY), and 0.1% in Corbus Pharmaceuticals Holdings (CRBP).


Latest Cara Therapeutics Inc News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.